Core Laboratories Inc

Core Laboratories Inc(CLB)股票分析

$10.130

+0.071 (+0.70%)收盤時

Loading chart…
最高
10.260
開盤
10.080
成交量加權均價
10.16
成交量
496.65K
市值
922.56M
最低
10.080
成交金額
5.04M
企業價值/稅息折舊攤銷前利潤(TTM)
11.37

Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. It assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

AI 分析 of Core Laboratories Inc (CLB)

持有

Core Laboratories Inc is currently a hold. The stock is trading at $10, which is significantly below its analyst price target of $21, indicating potential upside. However, the RSI is at 46.267, suggesting it is neither overbought nor oversold, and the stock has a year-to-date decline of 41%, indicating ongoing weakness. The main risk is the recent downgrade from BofA, which lowered its price target to $11, reflecting concerns about future performance.

分析師評級(18)

上檔空間 +13.52%
買進
10 買進
8 持有
0 賣出
目前: 10.13
最低
11.50
平均
11.50
最高
11.50

Johnson Rice

2026-08-13

目標價

$21

買進

BofA

2026-07-15

目標價

$11

落後大盤

Stifel

2025-07-16

目標價

$12

持有

Citi

2025-05-13

目標價

$13

中性

Stifel

2025-04-25

目標價

$13

持有

估值指標

Core Laboratories Inc(CLB)目前預期本益比為 19.76,5 年平均預期本益比為 23.26。

預期本益比

合理
5 年均值 P/E
23.26
目前P/E
19.76
高估
31.51
低估
15.02

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
14.95
目前EV/EBITDA
11.37
高估
19.89
低估
10.00

預期股價營收比

低估
5 年均值 P/S
1.66
目前P/S
0.89
高估
2.16
低估
1.17

Alphio AI 對 CLB 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CLB

$12.15

情境價格

基

基準

基準 · 50%CLB

$11.83

情境價格

悲

悲觀

悲觀 · 25%CLB

$9.77

情境價格

持有 CLB 的大戶

C

CWA Asset Management Group, LLC

+ 持有CLB

+7.26%

3個月報酬率

A

Ariel Investments, LLC

+ 持有CLB

-2.59%

3個月報酬率

事件時間軸

2026-07-29 (ET)

17:30:00

Core Lab Reports Q2 Revenue of $124.6M

17:30:00

Sees Q3 Revenue of $128.5M-$135.5M

2026-06-26 (ET)

17:30:00

S&P Global to Spin Off Mobility Global on July 1

2026-04-29 (ET)

17:00:00

Sees Q2 Revenue of $123M-$131M

17:00:00

Core Lab Q1 Revenue at $121.8M, Below Consensus

資訊

CLB 常見問題 —— 由 Alphio AI 解答

Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. It assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects. It operates in the Industrials sector (OIL & GAS FIELD SERVICES, NEC industry).

Core Laboratories Inc is currently a hold. The stock is trading at $10, which is significantly below its analyst price target of $21, indicating potential upside. However, the RSI is at 46.267, suggesting it is neither overbought nor oversold, and the stock has a year-to-date decline of 41%, indicating ongoing weakness. The main risk is the recent downgrade from BofA, which lowered its price target to $11, reflecting concerns about future performance.

18 analysts cover CLB: 10 rate it Buy, 8 Hold and 0 Sell. The average price target is 11.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易